{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:46:29Z","timestamp":1792791989409,"version":"4.5.0"},"reference-count":34,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Peritoneal metastases (PM) from colorectal cancer are associated with poor prognosis. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has been proposed for selected patients, although its role remains debated. This study evaluates the efficacy and safety of CRS plus HIPEC in a single institution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study included patients with colorectal PM treated with CRS and HIPEC between 2009 and 2024. Preoperative staging involved CT and\/or MRI, and all cases were discussed in a multidisciplinary team. Disease burden was assessed using the Peritoneal Cancer Index (PCI), and completeness of cytoreduction (CC score) was recorded. HIPEC was performed with oxaliplatin (360 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      at 42\u00b0C for 90 minutes). Overall survival (OS) was the primary endpoint; disease-free survival (DFS) and morbidity were secondary endpoints.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty patients (mean age 54 years) were included. Complete cytoreduction (CC-0\/1) was achieved in 88% of cases, with a median PCI of 8.33. Severe complications occurred in 18% of patients, with no 30-day mortality. After a median follow-up of 34 months, median OS was 49 months; 1- and 5-year OS rates were 96% and 54%, respectively. Median DFS was 14 months. PCI, CC score, and prior surgical score (PSS) were associated with OS on univariate analysis, while PCI and CC score remained independent prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CRS plus HIPEC is a feasible and effective treatment for selected patients with colorectal PM, with acceptable morbidity. Low PCI and complete cytoreduction are key predictors of improved survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2026-0041","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:00:24Z","timestamp":1788778824000},"page":"436-441","source":"Crossref","is-referenced-by-count":1,"title":["Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a single-institution experience"],"prefix":"10.2478","volume":"60","author":[{"given":"Gasper","family":"Pilko","sequence":"first","affiliation":[{"name":"1 Department Surgical Oncology, Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"2 Medical Faculty, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rok","family":"Petric","sequence":"additional","affiliation":[{"name":"1 Department Surgical Oncology, Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"2 Medical Faculty, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"2026090711001968781_j_raon-2026-0041_ref_001","doi-asserted-by":"crossref","unstructured":"Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014; 64: 104-17. doi: 10.3322\/caac.21220","DOI":"10.3322\/caac.21220"},{"key":"2026090711001968781_j_raon-2026-0041_ref_002","doi-asserted-by":"crossref","unstructured":"Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 2011; 128: 2717-25. doi: 10.1002\/ijc.25596","DOI":"10.1002\/ijc.25596"},{"key":"2026090711001968781_j_raon-2026-0041_ref_003","doi-asserted-by":"crossref","unstructured":"van Gestel YRBM, de Hingh IHJT, van Herk-Sukel MPP, van Erning FN, Beerepoot LV, Wijsman JH, et al. Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiol 2014; 38: 448-54. doi: 10.1016\/j.canep.2014.04.004","DOI":"10.1016\/j.canep.2014.04.004"},{"key":"2026090711001968781_j_raon-2026-0041_ref_004","doi-asserted-by":"crossref","unstructured":"Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol 2020; 25: 1-42. doi: 10.1007\/s10147-019-01485-z","DOI":"10.1007\/s10147-019-01485-z"},{"key":"2026090711001968781_j_raon-2026-0041_ref_005","doi-asserted-by":"crossref","unstructured":"Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of phase III trials N9741 and N9841. J Clin Oncol 2012; 30: 263-7. doi: 10.1200\/JCO.2011.37.1039","DOI":"10.1200\/JCO.2011.37.1039"},{"key":"2026090711001968781_j_raon-2026-0041_ref_006","doi-asserted-by":"crossref","unstructured":"Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: analysis from the ARCAD database. Lancet Oncol 2016; 17: 1709-19. doi: 10.1016\/S1470-2045(16)30500-9","DOI":"10.1016\/S1470-2045(16)30500-9"},{"key":"2026090711001968781_j_raon-2026-0041_ref_007","doi-asserted-by":"crossref","unstructured":"Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for colorectal peritoneal carcinomatosis. J Clin Oncol 2009; 27: 681-5. doi: 10.1200\/JCO.2008.19.7160","DOI":"10.1200\/JCO.2008.19.7160"},{"key":"2026090711001968781_j_raon-2026-0041_ref_008","doi-asserted-by":"crossref","unstructured":"Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in colorectal carcinomatosis. J Clin Oncol 2003; 21: 3737-43. doi: 10.1200\/JCO.2003.04.187","DOI":"10.1200\/JCO.2003.04.187"},{"key":"2026090711001968781_j_raon-2026-0041_ref_009","unstructured":"Sugarbaker PH, Gianola FJ, Speyer JC, Wesley R, Barofsky I, Meyers CE. Intravenous versus intraperitoneal 5-fluorouracil in advanced colorectal cancer. Surgery 1985; 98: 414-22. PMID: 3898450"},{"key":"2026090711001968781_j_raon-2026-0041_ref_010","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Prevention and treatment of peritoneal metastases: a comprehensive review. Indian J Surg Oncol 2019; 10: 3-23. doi: 10.1007\/s13193-018-0831-6","DOI":"10.1007\/s13193-018-0856-1"},{"key":"2026090711001968781_j_raon-2026-0041_ref_011","unstructured":"Koga S, Hamazoe R, Maeta M, Shimizu N, Kanayama H, Osaki Y. Continuous hyperthermic peritoneal perfusion in rats with intraperitoneal cancer. Cancer Res 1984; 44: 1840-2. PMID: 6424932"},{"key":"2026090711001968781_j_raon-2026-0041_ref_012","unstructured":"Elias D, Detroz B, Debaene B, Damia E, Leclercq B, Rougier R, et al. Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia: reliable and unreliable concepts. Hepatogastroenterology 1994; 41: 207-13. PMID: 7959539"},{"key":"2026090711001968781_j_raon-2026-0041_ref_013","doi-asserted-by":"crossref","unstructured":"Quenet F, Go\u00e9r\u00e9 D, Mehta SS, Roca L, Dumont F, Hessissen M, et al. Intraperitoneal oxaliplatin with or without irinotecan during HIPEC after CRS for colorectal carcinomatosis. Ann Surg 2011; 254: 294-301. doi: 10.1097\/SLA.0b013e3182263933","DOI":"10.1097\/SLA.0b013e3182263933"},{"key":"2026090711001968781_j_raon-2026-0041_ref_014","doi-asserted-by":"crossref","unstructured":"Sarmiento Bonilla CI, Maldonado J, Paredes Haro HD, Gonz\u00e1lez Mercado ZEDA, Dunay Silva AAA, Duran SPX, et al. Evaluation of the impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) on long-term survival and morbidity profile: a systematic review. Cureus 2026; 18: e106020. doi: 10.7759\/cureus.106020","DOI":"10.7759\/cureus.106020"},{"key":"2026090711001968781_j_raon-2026-0041_ref_015","doi-asserted-by":"crossref","unstructured":"Go\u00e9r\u00e9 D, Malka D, Tzanis D, Gava V, Boige V, Eveno C, et al. Curative potential after complete CRS and intraperitoneal chemotherapy for colorectal carcinomatosis. Ann Surg 2013; 257: 1065-71. doi: 10.1097\/SLA.0b013e31827b8a3e","DOI":"10.1097\/SLA.0b013e31827e9289"},{"key":"2026090711001968781_j_raon-2026-0041_ref_016","doi-asserted-by":"crossref","unstructured":"Chua TC, Yan TD, Saxena A, Morris DL. Cytoreductive surgery and HIPEC: morbidity and mortality. Ann Surg 2009; 249: 900-7. doi: 10.1097\/SLA.0b013e3181a45d86","DOI":"10.1097\/SLA.0b013e3181a45d86"},{"key":"2026090711001968781_j_raon-2026-0041_ref_017","doi-asserted-by":"crossref","unstructured":"Qu\u00e9net F, Elias D, Roca L, Go\u00e9r\u00e9 D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus HIPEC versus CRS alone for colorectal peritoneal metastases (PRODIGE 7). Lancet Oncol 2021; 22: 256-66. doi: 10.1016\/S1470-2045(20)30599-4","DOI":"10.1016\/S1470-2045(20)30599-4"},{"key":"2026090711001968781_j_raon-2026-0041_ref_018","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386-422. doi: 10.1093\/annonc\/mdw235","DOI":"10.1093\/annonc\/mdw235"},{"key":"2026090711001968781_j_raon-2026-0041_ref_019","doi-asserted-by":"crossref","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications. Ann Surg 2004; 240: 205-13. doi: 10.1097\/01.sla.0000133083.54934.ae","DOI":"10.1097\/01.sla.0000133083.54934.ae"},{"key":"2026090711001968781_j_raon-2026-0041_ref_020","doi-asserted-by":"crossref","unstructured":"Spiliotis J, Kalles V, Kyriazanos I, Terra A, Prodromidou A, Raptis A, et al. CRS and HIPEC in colorectal peritoneal metastases. Pleura Peritoneum 2019; 4: 20190018. doi: 10.1515\/pp-2019-0018","DOI":"10.1515\/pp-2019-0018"},{"key":"2026090711001968781_j_raon-2026-0041_ref_021","doi-asserted-by":"crossref","unstructured":"Glehen O, Cotte E, Schreiber V, Sayag-Beaujard AC, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia and cytoreductive surgery for colorectal peritoneal carcinomatosis. Br J Surg 2004; 91: 747-54. doi: 10.1002\/bjs.4474","DOI":"10.1002\/bjs.4473"},{"key":"2026090711001968781_j_raon-2026-0041_ref_022","doi-asserted-by":"crossref","unstructured":"Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer. J Clin Oncol 2004; 22: 3284-92. doi: 10.1200\/JCO.2004.10.012","DOI":"10.1200\/JCO.2004.10.012"},{"key":"2026090711001968781_j_raon-2026-0041_ref_023","doi-asserted-by":"crossref","unstructured":"Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol 2004; 11: 178-86. doi: 10.1245\/ASO.2004.03.012","DOI":"10.1245\/ASO.2004.05.009"},{"key":"2026090711001968781_j_raon-2026-0041_ref_024","doi-asserted-by":"crossref","unstructured":"Chow FC, Yip J, Foo DC, Wei R, Choi HK, Ng KK, et al. Cytoreductive surgery and HIPEC for colorectal and appendiceal peritoneal metastases. Asian J Surg 2021; 44: 221-8. doi: 10.1016\/j.asjsur.2020.05.021","DOI":"10.1016\/j.asjsur.2020.05.010"},{"key":"2026090711001968781_j_raon-2026-0041_ref_025","doi-asserted-by":"crossref","unstructured":"van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HW, Hermans RH, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018; 378: 230-40. doi: 10.1056\/NEJMoa1708618","DOI":"10.1056\/NEJMoa1708618"},{"key":"2026090711001968781_j_raon-2026-0041_ref_026","doi-asserted-by":"crossref","unstructured":"Levine EA, Stewart JH, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy: experience with 1,000 patients. J Am Coll Surg 2014; 218: 573-85. doi: 10.1016\/j.jamcollsurg.2013.12.037","DOI":"10.1016\/j.jamcollsurg.2013.12.013"},{"key":"2026090711001968781_j_raon-2026-0041_ref_027","doi-asserted-by":"crossref","unstructured":"Kirstein MN, Root SA, Moore MM, Wieman KM, Williams BW, Jacobson PA, et al. Exposure-response relationships for oxaliplatin. Anticancer Drugs 2008; 19: 37-44. doi: 10.1097\/CAD.0b013e3282f15acb","DOI":"10.1097\/CAD.0b013e3282f07791"},{"key":"2026090711001968781_j_raon-2026-0041_ref_028","doi-asserted-by":"crossref","unstructured":"Lemoine L, Thijssen E, Carleer R, Geboers K, Sugarbaker P, van der Speeten K. COBOX trial: intraperitoneal chemotherapy dosing. J Surg Oncol 2019; 119: 999-1010. doi: 10.1002\/jso.25442","DOI":"10.1002\/jso.25437"},{"key":"2026090711001968781_j_raon-2026-0041_ref_029","doi-asserted-by":"crossref","unstructured":"Ceelen W. HIPEC with oxaliplatin for colorectal metastasis. Eur J Surg Oncol 2019; 45: 400-2. doi: 10.1016\/j.ejso.2018.11.513","DOI":"10.1016\/j.ejso.2018.10.542"},{"key":"2026090711001968781_j_raon-2026-0041_ref_030","doi-asserted-by":"crossref","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in peritoneal carcinomatosis. Cancer Treat Res 1996; 82: 359-74. doi: 10.1007\/978-1-4613-1247-5_23","DOI":"10.1007\/978-1-4613-1247-5_23"},{"key":"2026090711001968781_j_raon-2026-0041_ref_031","doi-asserted-by":"crossref","unstructured":"Simkens GA, Rovers KP, Nienhuijs SW, de Hingh IH. Patient selection for CRS and HIPEC. Cancer Manag Res 2017; 9: 259-66. doi: 10.2147\/CMAR.S119569","DOI":"10.2147\/CMAR.S119569"},{"key":"2026090711001968781_j_raon-2026-0041_ref_032","doi-asserted-by":"crossref","unstructured":"Cao C, Yan TD, Black D, Morris DL. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2009; 16: 2152-65. doi: 10.1245\/s10434-009-0487-4","DOI":"10.1245\/s10434-009-0487-4"},{"key":"2026090711001968781_j_raon-2026-0041_ref_033","unstructured":"Newton AD, Bartlett EK, Karakousis GC. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality. J Gastrointest Oncol 2016; 7: 99-111. doi: 10.3978\/j.issn.2078-6891.2015.114"},{"key":"2026090711001968781_j_raon-2026-0041_ref_034","doi-asserted-by":"crossref","unstructured":"Foster JM, Sleightholm R, Patel A, Shostrom V, Hall B, Neilsen B, et al. Morbidity and mortality after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. JAMA Netw Open 2019; 2: e187346. doi: 10.1001\/jamanetworkopen.2018.7346","DOI":"10.1001\/jamanetworkopen.2018.6847"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2026-0041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:00:45Z","timestamp":1788778845000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2026-0041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9,7]]},"published-print":{"date-parts":[[2026,9,1]]}},"alternative-id":["10.2478\/raon-2026-0041"],"URL":"https:\/\/doi.org\/10.2478\/raon-2026-0041","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}